94. 原発性硬化性胆管炎 Primary sclerosing cholangitis Clinical trials / Disease details

臨床試験数 : 148 / 薬物数 : 118 - (DrugBank : 39) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 141

8 trials found

diseases per page:

Showing 1 to 8 of 8 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04309773 (ClinicalTrials.gov)	April 6, 2021	18/10/2019	Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis De ...	Double Blind, Multicentric, Randomized, Placebo-controlled Trial, Evaluating the Efficacy of 24 Mont ...	Primary Sclerosing Cholangitis;Cholestasis	Drug: Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCAtherapy;Drug: Placebo of Bezaf ...	Assistance Publique - Hôpitaux de Paris	NULL	Recruiting	18 Years	75 Years	All	104	Phase 3	France
2	NCT03678480 (ClinicalTrials.gov)	March 1, 2021	18/9/2018	A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)	A Phase 2, Randomized, Double-Blind Study of HTD1801 vs Ursodeoxycholic Acid(UDCA) in Adolescents Wi ...	Primary Sclerosing Cholangitis;Cholangitis;Cholangitis, Sclerosing;Bile Duct Diseases;Biliary Tract ...	Drug: HTD1801;Drug: Ursodeoxycholic Acid	HighTide Biopharma Pty Ltd	NULL	Withdrawn	12 Years	17 Years	All	0	Phase 2	NULL
3	EUCTR2019-001015-23-FR (EUCTR)	13/05/2020	04/06/2020	Study evaluating the efficacy of bezafibrate for people suffering of primary sclerosing cholangitis	Double blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-mont ...	Adult patients with primary sclerosing cholangitis;Therapeutic area: Diseases [C] - Digestive System ...	Trade Name: BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée Product Name: bezafibrate Produ ...	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	104	Phase 3	France
4	NCT03516006 (ClinicalTrials.gov)	January 2017	20/9/2017	Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis	Intra-arterial Injection of Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis	Primary Sclerosing Cholangitis	Drug: UCMSC;Drug: UDCA	Fuzhou General Hospital	NULL	Active, not recruiting	18 Years	65 Years	All	20	Phase 1/Phase 2	NULL
5	EUCTR2015-003310-24-SE (EUCTR)	09/10/2015	01/09/2015	Ursodeoxycholic Acid(UDCA) in Preventing Hepatobiliary and Colorectal Malignancy in Surveillance Pat ...	A Phase 3, Open-label, Randomized, Prospective Clinical Trial Evaluating the Efficacy of Stratified ...	Primary sclerosing cholangitis with or without concomitant inflammatory bowel disease included in an ...	Trade Name: Ursofalk Product Name: Ursofalk	Sahlgrenska Academy	NULL	Not Recruiting			Female: yes Male: yes	500	Phase 3	Sweden
6	NCT01456468 (ClinicalTrials.gov)	October 2011	14/10/2011	Combination Therapy With Ursodeoxycholic Acid(UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment ...	Combination Therapy With Ursodeoxycholic Acid(UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment ...	Cholangitis, Sclerosing	Drug: Oral all-trans retinoic acid (ATRA)	Yale University	Mayo Clinic	Completed	18 Years	80 Years	Both	19	Phase 1	United States
7	NCT01088607 (ClinicalTrials.gov)	October 2010	12/3/2010	Safety and Efficacy Study of Ursodeoxycholic AcidTherapy in Pediatric Primary Sclerosing Cholangitis ...	Ursodeoxycholic AcidTherapy in Pediatric Primary Sclerosing Cholangitis: A Pilot Withdrawal/Reinstit ...	Primary Sclerosing Cholangitis	Drug: ursodeoxycholic acid (UDCA)	University of Tennessee	Icahn School of Medicine at Mount Sinai;Ann & Robert H Lurie Children's Hospital of Chicago;Universi ...	Completed	5 Years	21 Years	All	27	Phase 1	United States;Canada
8	NCT00059202 (ClinicalTrials.gov)	April 2003	21/4/2003	Trial of High-dose Urso in Primary Sclerosing Cholangitis	Multicentered Randomized Trial of High-dose Urso in Primary Sclerosing Cholangitis	Sclerosing Cholangitis	Drug: Ursodeoxycholic Acid	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NULL	Completed	18 Years	75 Years	Both	150	Phase 2/Phase 3	United States

First Previous1Next Last